Revolutionizing Brain Tumor Detection
One Tear at a Time
Biodrop Solutions is pioneering a non-invasive diagnostic platform that utilizes tear-based microRNA analysis to detect gliomas early, before symptoms appear, without the need for needles or biopsies.
We are developing single-use, biocompatible contact lenses that gently collect tear fluid for analysis—enabling early detection of brain tumors through microRNA profiling.
Why Tears?
Tears are connected to brain physiology via the lacrimal system
Contain high levels of stable microRNAs—key cancer biomarkers
Enable safe, stress-free sample collection
No hospital visit, no blood draw, no lumbar puncture
The Future of Liquid Biopsy Is in the Eye
Our Mission/Solution
Why This Matters
Every year, approximately 250,000 people are diagnosed with malignant brain tumors. Gliomas account for about 80% of these cases, and early detection can save lives.
Traditional diagnostic methods:
invasive procedures (biopsies or CSF tap)
Expensive and hospital-based
Often delayed until late-stage symptoms appear
Deliver affordable, non-invasive diagnostics that improve outcomes and reduce anxiety for millions.
Rapid, pain-free, tear-based diagnostics
Built around a unique microRNA signature in tear samples
Validated for sensitivity and specificity in glioma detection
What Makes Us Different:
Transforming Tears into Diagnostic Innovations
At Biodrop Solutions, we are pioneering contact lenses that collect tears for liquid biopsies, revolutionizing early disease detection and monitoring through our unique hydrogel technology.
We are presenting a fresh and innovative approach:
Contact lens collection platform — IP-protected hydrogel lens designed to preserve sample integrity
Automated microRNA analysis — built for high-throughput clinical workflows
Affordable and scalable — opening access to underserved populations
Focus Area: Gliomas First
Our technology roadmap begins with glioma detection, then expands to neurodegenerative diseases like Alzheimer’s and Parkinson’s in future phases.
Revolutionary Tear Diagnostics
Transforming tears into diagnostic tools for early disease detection and monitoring with innovative technology.
Tear Collection Technology
Imagine a world where diagnosing brain tumors and neurodegenerative diseases is as simple as shedding a tear. Our project aims to achieve this with a revolutionary tear collection method.
We are creating a biocompatible, single-use lens that collects and preserves genetic samples from tears while ensuring patient comfort. The material we use regulates pH levels, which is vital for maintaining the integrity of microRNAs. This innovative approach provides a quick, non-invasive, and painless alternative to traditional diagnostic blood or CSF tests.
Liquid biopsy screening is a significant advancement in cancer diagnostics, enabling early detection and continuous monitoring by analyzing circulating DNA, exosomes, and cell-free RNA. This approach provides real-time insights and overcomes traditional diagnostic limitations.
Additionally, tear collection offers a non-invasive and safe diagnostic method ensuring a comfortable experience for patients.
Our goal is to deliver unique services at low costs, creating an untapped market space that attracts a wider audience and redefines healthcare standards.
Tears provide a unique advantage for assessing biomarkers related to brain pathologies due to their connection with the lacrimal and meibomian glands and the brain.
They contain diverse molecular components, including significant amounts of microRNAs, which regulate around 60% of human protein-coding genes. Abnormal expression of these microRNAs is closely linked to cancer development, underscoring their diagnostic potential in health and disease.
Tears
Liquid biopsy
Brain cancer diagnosis
An innovative tear microRNA analysis for early non-invasive glioma diagnosis
Every year, more than 250,000 new cases of primary malignant brain tumors are diagnosed globally, with gliomas representing approximately 80% of these alarming figures. A myriad of factors contributes to an individual's risk of developing gliomas, including age and race, which are unfortunately beyond our control. Nevertheless, there is a glimmer of hope in the realm of early detection and intervention for low-grade gliomas. When these early-stage tumors are identified swiftly, they can be managed with greater efficacy, potentially slowing their progression and diminishing the risk of their advancement to more aggressive, high-grade gliomas. By emphasizing early intervention, we can significantly improve outcomes and enhance the quality of life for patients at risk.
Traditionally, diagnosing brain tumors has involved invasive procedures, such as tissue biopsies, which can be a source of unnecessary anxiety and present risks for patients who may not even have cancer. In light of this, we propose a more compassionate and innovative approach: a non-invasive alternative that analyzes microRNA present in tears to detect gliomas in their nascent stages.
Our hypothesis suggests that a unique microRNA signature found in tear samples may serve as an indicator of glioma presence. This groundbreaking method has the potential to pave the way for the development of rapid, cost-effective, and non-invasive screening tests. A diagnostic technique centered around tear analysis could revolutionize the way healthcare providers detect and monitor brain tumors, with the prospect of early detection saving countless lives.
The underlying science of tear-based liquid biopsy holds tremendous promise, and we are committed to developing a cutting-edge sample collection method paired with advanced microRNA analysis technology. My strategy for clinical implementation appears highly promising. This straightforward yet powerful diagnostic tool could significantly enhance the efficacy of glioma detection worldwide, transforming the landscape of brain tumor diagnostics for clinicians and patients alike.
★★★★★
Contact Us for Innovative Solutions
Reach out to learn more about our groundbreaking tear-collecting technology.
